Wednesday, November 16, 2011
ProFibrix BV, of Leiden, the Netherlands, said its Phase II trial with Fibrocaps in liver resection surgery resulted in a 50 percent reduction in mean time to hemostasis the primary endpoint compared to active control. The study enrolled 56 patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.